Long Island Clinical Research Associates

Great Neck, New York 71105

0 studies enrolling now · 31 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Distal Ulcerative Colitis, Diverticulitis, Gastrointestinal Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Left-sided Ulcerative Colitis, Perianal Crohn's Disease, Ulcerative Colitis

Studies at this site

• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease — Completed
• Extension Study of Semapimod 60 mg IV x 3 Days — Completed
• A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease — Stopped early
• Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Prevention of Recurrence of Diverticulitis — Completed
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease — Completed
• Efficacy and Safety Study of Ozanimod in Ulcerative Colitis — Completed
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease — Completed
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis — Completed
• Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis — Status unconfirmed
• LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) — Completed
• CNI-1493 for Treatment of Moderate to Severe Crohn's Disease — Stopped early
• Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome — Completed
• A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome — Completed
• Remission in Subjects With Crohn's Disease, 1 Year Phase — Completed
• Remission in Subjects With Crohn's Disease, Open Label Extension — Completed
• Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis — Completed
• Study for the Treatment of Crohn's Disease With Adacolumn — Completed
• Study for the Treatment of Ulcerative Colitis With Adacolumn — Completed
• CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission — Completed
• An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease — Completed
• A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease — Completed
• Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis — Completed